Author

R. Weersma

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Importance of faecal sample collection in prospective cohort studies to evaluate the effect of the gut microbiome on cancer development.

The gut microbiome has been linked to cancer in many cross-sectional studies. These studies compared individuals with and without cancer, but they do not establish causation. Prospective cohort studies, with faecal samples collected before a cancer diagnosis, will be instrumental in assessing the role of the gut microb...

E. Vogtmann, Caroline Y. Um, S. Zouiouich et al. · The Lancet Microbe · 0 citations

Open access Sep 2026

A gut microbiome-derived risk score is associated with future cancer development

Cancer remains a leading cause of morbidity and mortality worldwide, and the incidence of new cancer cases is rising. While established lifestyle factors such as smoking, obesity, and diet contribute to cancer risk, the gut microbiome has emerged as a hallmark of cancer. However, the role of the gut microbiome in cance...

E. Oosterhout, R. S. Leijdesdorff, O. Kambur et al. · medRxiv · 0 citations

Open access Oct 2026

Genome-wide analysis of genetic modifiers of Crohn's disease and ulcerative colitis risk in response to tobacco smoking.

BACKGROUND Gene-environment interactions (GxE) are fundamental for understanding the mechanisms of human diseases. Tobacco smoking is of particular interest for Inflammatory bowel disease (IBD), as it worsens Crohn's disease (CD) but protects against ulcerative colitis (UC). Here, we systematically examined the genome-...

Jing-Jing Bai, R. Gacesa, J. Björk et al. · EBioMedicine · 0 citations

Sep 2026

Gut microbiome alterations predictive of cancer risk

It is shown that people who are diagnosed with cancer after microbiome sampling have microbiome alterations like those found in diagnosed cancer cases, albeit to a lower degree, across the four populations studied, indicating that the microbiome may evolve towards the one found in cancer well before cancer is diagnosed...

G. Vitali, J. Bjork, O. Kambur et al. · medRxiv · 0 citations

Aug 2026

Upadacitinib effectively suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn's disease tissue.

Interleukin-13 receptor alpha 2 (IL13RA2) is highly expressed in intestinal inflammation-associated fibroblasts (IAFs) and is associated with anti-tumor necrosis factor alpha (TNF-α) therapy resistance in inflammatory bowel disease (IBD). Because IL13RA2 inhibition ameliorates experimental colitis in mice, we investiga...

Li Wang, Ruibin Wu, Sofie de Jong et al. · Biochemical Pharmacology · 0 citations